Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Ayvakit (avapritinib) is a kinase inhibitor indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. It is also approved for the treatment of advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. Ayvakit selectively inhibits mutated forms of KIT and PDGFRA kinases, which are key drivers of disease progression in these patient populations.
| Fact Table | |
| Formula | C27H27F5N8O |
| License | US FDA (2020) |
| Bioavailability | ~60% (oral) |
| Legal status | Prescription only |
| Chemical Name | Ripretinib |
| Elimination half-life | 14 hours |
| Dosage (Strength) | 150 mg tablets |
| Pregnancy | Category D – Risk to fetus |
| Brands | Qinlock |
| Protein binding | 99.8% |
| PubChem CID | 71277963 |
| MedlinePlus | a620043 |
| ChEBI | Not available |
| ATC code | L01EX19 |
| DrugBank | DB15188 |
| KEGG | D11816 |
| Routes of administration | Oral |
Ayvakit is administered orally once daily on an empty stomach. For GIST with PDGFRA exon 18 mutations, the recommended dose is 300 mg once daily. For AdvSM, the starting dose is 200 mg once daily. Dose adjustments may be necessary based on tolerability, hepatic impairment, or drug interactions. Treatment should continue until disease progression or unacceptable toxicity occurs. Ayvakit should be prescribed and monitored by physicians experienced in the use of antineoplastic therapies.
Active ingredient: avapritinib Inactive ingredients include: colloidal silicon dioxide, mannitol, microcrystalline cellulose, sodium stearyl fumarate, and sodium starch glycolate. The film coating contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and FD&C Blue #2 aluminum lake (for the 300 mg tablet).
There are no absolute contraindications listed in the prescribing information. However, Ayvakit is not recommended for use in patients with moderate to severe hepatic impairment due to increased exposure and potential toxicity.
Cognitive effects, including memory impairment, confusion, and hallucinations, have been reported. Patients should be monitored for neurological symptoms, and dose modification or discontinuation may be required. Intracranial hemorrhage has also occurred and may be fatal; any new neurological symptoms should prompt immediate evaluation. Ayvakit can cause embryo-fetal harm and should not be used during pregnancy. Effective contraception is advised during treatment and for at least six weeks after the last dose.
Common side effects may include:
Serious adverse effects may include intracranial hemorrhage, severe cognitive effects, and anemia.
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews